Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Sign up for our daily digest of everything you need to know about San Diego — just the essentials, every morning.
By clicking sign up, you agree to the terms.